Orforglipron and Tesamorelin Interaction

Monitor
Mechanism-based 50% confidence

Orforglipron and Tesamorelin have an interaction requiring monitoring for interaction with 50% confidence. Both Orforglipron and Tesamorelin promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually. Both compounds affect the gi tract, so monitoring these systems is recommended.

Compound Profiles

Orforglipron

Oral Small-Molecule GLP-1 Receptor Agonist | Weight Loss & Diabetes

Small-molecule GLP-1 receptor agonist with biased signaling preferentially activating G protein/cAMP pathways, enhancing insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite while minimizing receptor desensitization. 79.

Half-life: 25-68 hours Typical dose: Start 3-6mg daily, titrate up to 12-36mg based on response weight loss, metabolic
glp1 receptor teratogenic
View full profile

Tesamorelin

GHRH Analog | Visceral Fat Reduction

Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation, selectively targeting visceral adipose tissue while sparing subcutaneous fat..

Half-life: 26-38 minutes Typical dose: 1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) growth hormone, weight loss
ghrh receptor carcinogenic riskinsulin disruptingteratogenic
View full profile

Combined Organ Load

GI Tract
low
Pancreas
low
Pituitary
low

Shared Safety Flags

2x 2 compounds share the teratogenic safety flag (Orforglipron, Tesamorelin). Monitor accordingly.

Frequently Asked Questions

Can I take Orforglipron with Tesamorelin?

Yes, but with caution. Both Orforglipron and Tesamorelin promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually. Regular monitoring is advised.

Is Orforglipron and Tesamorelin safe together?

Based on pharmacological analysis, this combination is considered monitor. However, shared safety flags include: teratogenic. Monitor accordingly.

What are the interactions between Orforglipron and Tesamorelin?

Both Orforglipron and Tesamorelin promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually. This assessment has 50% confidence and is inferred from pharmacological mechanism analysis.

How should I time Orforglipron and Tesamorelin?

Orforglipron has a half-life of 25-68 hours and Tesamorelin has a half-life of 26-38 minutes. No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Orforglipron vs Tesamorelin

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.